CSV January 31, 2023 through January 31, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POTASSIUM M SPECIFIC		*USP36–NF31*	2172	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First*	Line 1: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ETAPHOSPHATE	TESTS/ *Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912>*						*Supplement to USP37–NF32*	and to: or
ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS	IM PUR ITIES/*Organic Impurities, Procedure 2*	*First Supplement to USP36–NF31*	5996	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 3: Change the section head *Isosorbide mononitrate related compound A stock solution:* to: *Isosorbide mononitrate related compound A standard stock solution:* AND Line 7: Change the section head *Isosorbide dinitrate stock solution:* to: *Isosorbide*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dinitrate standard stock solution: AND Line 3 of *Standard stock solution*: Change *Isosorbide mononitrate related compound A stock solution* and *Isosorbide dinitrate stock solution*, to: *Isosorbide mononitrate related compound A standard stock solution* and *Isosorbide dinitrate standard stock solution*,
SORBITAN SESQUIOLEATE	IDENTIFICATION/*A.*	*USP36–NF31*	2215	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Sample*: Change 1 g of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								residue obtained in the *Assay for Fatty Acids* to: Residue obtained in the *Assay for Fatty Acids* AND Line 2 of *Acceptance criteria*: Change 192–204 to: 192–204 on 1-g sample
PANCURONIUM BROMIDE INJECTION	IMPURITIES/*Organic Impurities*	*Second Supplement to USP36–NF31*	6677	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Footnote a of *Table 1*: Change Piperidinium, 1-[(2,3,5,16,17)-17-acetyloxy-3-hydroxy-2-(1-piperidinyl)androstan-16-yl]-1-methyl bromide. to: Piperidinium, 1-[(2,3,5,16,17)-17-acetyloxy-3-h

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ydroxy-2-(1-piperidinyl)androstan-16-yl]-1-methyl.
CAFFEINE CITRATE INJECTION	*Assay*	*USP36–NF31*	2732	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 3 of *Chromatographic system*: Change 150-cm column to: 15-cm column
BEHENOYL POLYOXYLGLYCERIDES	IMPURITIES/*Limit of Free Glycerol /Titrimetric system*	*USP36–NF31*	1892	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Mode*: Change Direct titration to: Residual titration
ESOMEPRAZOLE MAGNESIUM	SPECIFIC TESTS/*Color of Solution*	*USP36–NF31*	3464	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Sample solution*: Change 20 mg/mL of Esomeprazole Magnesium in methanol to: 20 mg/mL of Esomeprazole Magnesium in methanol, filtered

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
EGG PHOSPHOLIPIDS	ASSAY/*Content of Phospholipids*	*USP36–NF31*	2000	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2 of *Solution A*: Change acetic acid to: glacial acetic acid AND Line 2 of *Solution B*: Change acetic acid to: glacial acetic acid
OCTOCRYLENE	*Identification, Ultraviolet Absorption <197U>*	*USP36–NF31*	4557	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 4: Change Absorptivities, calculated on the as-is basis, to: Absorptivity at 303 nm, calculated on the as-is basis,
LAUROYL POLYOXYLGLYCERIDES	IMPURITIES/*Limit of Free Glycerol*	*USP36–NF31*	2064	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Mode* in *Titrimetric system*: Change Direct titration to: Residual titration

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Line 10 of *Analysis*: Change (V_S ? V_B) to: (V_B ? V_S) AND Line 11 of *Analysis*: Change V_S = *Titrant* volume consumed by the *Sample* (mL) V_B = *Titrant* volume consumed by the *Blank* (mL) to: V_B = *Titrant* volume consumed by the *Blank* (mL) V_S = *Titrant* volume consumed by the *Sample* (mL)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
RIMEXOLONE OPHTHALMIC SUSPENSION	*Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912>*	*USP36–NF31*	5053	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1: Change and to: or
POLYOXYL 20 CETOSTEARYL ETHER	SPECIFIC TESTS/*Average Polymer Length*	*USP36–NF31*	2155	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 16 of *Analysis*: Change Result = [32 × $A_2/(A_1$? 3)]/4 to: Result = [(32 × A_2/A_1) ? 3]/4
URSODIOL TABLETS	IM PURITIES/*Organic Impurities*/*Procedure*	*USP36–NF31*	5520	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2 of *Sample solution*: Change Tablets, equivalent to about 25 mg of ursodiol, to: Tablets, equivalent to about 250 mg of ursodiol,
SORBITAN MONOPALMITATE	IDENTIFICATION/*A.*	*USP36–NF31*	2213	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Sample*: Change 1 g of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								residue obtained in the *Assay for Fatty Acids* to: Residue obtained in the *Assay for Fatty Acids* AND Line 2 of *Acceptance criteria*: Change 210–225 to: 210–225 on 1-g sample
BETHANECHOL CHLORIDE	IMPURITIES/*Heavy Metals, Method 1 <231>*	*Second Supplement to USP36–NF31*	6568	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Test preparation*: Change Bethacholine Chloride to: Bethanechol Chloride
STEARYL ALCOHOL	SPECIFIC TESTS/*Fats and Fixed Oils, Hydroxyl Value <401>*	*USP36–NF31*	2252	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 14 of *Analysis:* Change $[(V_S ? V_B) \times N \times F]/W$ to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$[(V_B ? V_S) \times N \times M_r]/W$ AND Line 15 of *Analysis*: Change V_S = volume of 1 N sodium hydroxide consumed by the sample (mL) V_B = volume of 1 N sodium hydroxide consumed by the blank test (mL) to: V_B = volume of 1 N sodium hydroxide consumed by the blank test (mL) V_S = volume of 1 N sodium hydroxide consumed by the sample (mL) AND Line 21 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Analysis: Change *F* = molecular weight of potassium hydroxide, 56.11 to: M_r = molecular weight of potassium hydroxide, 56.11
ACETYLTRIBUTYL CITRATE	IDENTIFICATION/*B.*	*USP36–NF31*	1869	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2: Change USP Acetyltriethyl Citrate RS to: USP Acetyltributyl Citrate RS
CLAVULANATE POTASSIUM	IMPURITIES/*Organic Impurities/Procedure 3: Limit of Aliphatic Amines*	*USP36–NF31*	3022	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	In the definition list in *Analysis*: Change C_U = nominal concentration of Clavulanate Potassium in the *Standard solution* to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								C_U = nominal concentration of Clavulanate Potassium in the *Sample solution*
CETOSTEARYL ALCOHOL	SPECIFIC TESTS/*Fats and Fixed Oils, Hydroxyl Value <401>*	*USP36–NF31*	1954	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Mode* in *Titrimetric system*: Change Direct titration to: Residual titration AND Line 16 of *Analysis*: Change Result = [(V_S ? V_B) × F]/W to: Result = [(V_B ? V_S) × N × M_r]/W AND Line 17 of *Analysis*: Change V_S = *Titrant* volume consumed by the *Sample* (mL)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								V_B = *Titrant* volume consumed by the *Blank* (mL) *F* = calculation factor, 56.1 to: V_B = *Titrant* volume consumed by the *Blank* (mL) V_S = *Titrant* volume consumed by the *Sample* (mL) *N* = actual normality of 1 N sodium hydroxide (mEq/mL) M_r = molecular weight of potassium hydroxide, 56.11
MERCAPTOPURINE TABLETS	IMPURITIES/*Organic Impurities/Procedure*	*USP36–NF31*	4249	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 6 of *Sample stock solution*: Change Dilute with

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								water to volume. to: Dilute with *Solution A* to volume.
GLYCERYL MONOLINOLEATE	ASSAY/ *Procedure*	*USP36–NF31*	2030	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 13 of *Chromatographic system*: Change *Column temperature*: 40° to: *Temperatures Detector*: 40° *Column*: 40°
QUININE SULFATE	IM PURITIES/ *Dihydroquinine Sulfate*	*USP36–NF31*	4995	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 5 of *Analysis*: Change Result = (r_U/r_S) × 100 to: Result = $r_U/(r_U + r_S)$ × 100
POLYISOBUTYLENE	IM PURITIES/*Lead <251>*	*USP36–NF31*	2149	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Acceptance criteria*: Change NMT 3 mg/g to: NMT 3 ?g/g

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TERAZOSIN CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Test 1/Spectrometric conditions*	*USP36–NF31*	5308	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Analytical wavelength*: Change UV 245 nm to: UV 246 nm AND Line 3 of *Cell length*: Change 0.2 cm for Capsules labeled to contain 10 mg to: 0.5 cm for Capsules labeled to contain 10 mg
SORBITAN MONOLAURATE	IDENTIFICATION/*A.*	*USP36–NF31*	2212	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Sample*: Change 1 g of the residue obtained in the *Assay for Fatty Acids* to: Residue obtained in the *Assay for Fatty*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Acids AND Line 2 of *Acceptance criteria*: Change 260–280 to: 260–280 on 1-g sample
LOPINAVIR AND RITONAVIR TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*First Supplement to USP36–NF31*	6005	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Tolerances*: Change 80.0% to: 80%
SORBITAN TRIOLEATE	IDENTIFICATION/*A.*	*USP36–NF31*	2216	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Sample*: Change 1 g of the residue of oleic acid obtained in the *Assay for Fatty Acids* to: Residue obtained in the *Assay for Fatty Acids* AND Line 2 of *Acceptance*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								criteria: Change 192–204 to: 192–204 on 1-g sample
POLYMYXIN B SULFATE	IM PURITIES/*Organic Impurities*	*Second Supplement to USP36–NF31*	6686	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2: Change *Buffer, Mobile phase, Diluent, Sensitivity solution,* to: *Buffer, Mobile phase, Diluent, Standard solution, Sensitivity solution,* AND Line 1 of *Samples* in *Analysis*: Change *Standard solution*, *Sample solution*, and *Sensitivity solution* to: *Sample solution*
ELEMENTAL I	DRUG	*USP36–NF31*	151	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First*	Line 17 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MPURITIES—LIP MITS	RO DUCTS/*Options for Demonstrating Compliance*						*Supplement to USP37–NF32*	*Summation Option*: Change the manufacturer must validate to: the manufacturer must ensure
CAFFEINE CITRATE ORAL SOLUTION	*Assay*	*USP36–NF31*	2733	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 3 of *Chromatographic system*: Change 150-cm column to: 15-cm column
BETADEX	IM PURITIES/*Limit of Reducing Sugars*	*USP36–NF31*	1905	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 3 of *Tartrate solution*: Change 20 mg/mL of anhydrous sodium sulfate to: 200 mg/mL of anhydrous sodium sulfate
ETHIODIZED OIL INJECTION	*Viscosity—Capillary Viscometer Methods <911> and Rotational*	*USP36–NF31*	3505	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1: Change and to: or

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Rheometer Methods <912>							
DIPHENHYDRAMINE HYDROCHLORIDE INJECTION	*Assay*	*USP36–NF31*	3276	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2: Change *Mobile phase*, *Standard preparation*, *System suitability solution*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Diphenhydramine Hydrochloride*. to: *Mobile phase*—Prepare a solution of acetonitrile, water, and triethylamine (50: 50: 0.5), adjust with glacial acetic acid to a pH of 6.5, filter, and degas. Make adjustments if

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								necessary (see *System Suitability* under *Chromatography* <621>). *Standard preparation*—Dissolve an accurately weighed quantity of USP Diphenhydramine Hydrochloride RS in water to obtain a solution having a known concentration of about 0.5 mg per mL. AND After the *Assay preparation* subsection: Add *System suitability solution*—Dissolve about 5 mg of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								benzophenone in 5 mL of acetonitrile, dilute with water to 100 mL, and mix. Transfer 1.0 mL of this solution and 5 mg of diphenhydramine hydrochloride to a 10-mL volumetric flask, dilute with water to volume, and mix. *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 25-cm column that contains packing L10. The flow rate is about 1 mL per

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								minute. Chromatograph the *System suitability solution*, and record the peak responses as directed for *Procedure*; the resolution, *R*, between the benzophenone and diphenhydramine peaks is not less than 2.0. Chromatograph replicate injections of the *Standard preparation*, and record the peak responses as directed for *Procedure*; the relative standard deviation is not more than 2.0%, and the tailing factor for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the diphenhydramine hydrochloride peak is not more than 2.0. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Diphenhydramine Hydrochloride*. to: Separately inject equal volumes, about 10 ?L, of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								for the major peaks.
FEXOFENADINE HYDROCHLORIDE TABLETS	ASSAY/ *Procedure*	*USP36–NF31*	3576	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 6 of *Sample stock solution*: Change (equivalent to 80% of the total flask volume) to: (sufficient to fill the flask to 80% of its volume)
NIFEDIPINE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 4/Instrumental conditions*	*USP36–NF31*	4509	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Cell*: Change 0.5 cm to: 1 cm
GYMNEMA	IDENTIFICATION/*B. Thin-Layer Chromatography*/ *Chromatographic system*	*First Supplement to USP36–NF31*	5880	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2 of *Adsorbent*: Change 5m to: 5 µm
POWDERED STINGING NETTLE EXTRACT	COMPOSITION/*Content of Total Amino Acids*	*USP36–NF31*	1608	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Reagent solution*: Change Solution

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								containing 1.00 g of ninhydrin, 1.50 g of hydrindantin, to: Solution containing 1.00 g of ninhydrin, 150 mg of hydrindantin,
OXCARBAZEPINE	IMPURITIES/*Organic Impurities, Procedure 1*	*First Supplement to USP36–NF31*	6035	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Row 4 of Column 1 of *Table 1*: Change Dibenzazepinone[b] to: Oxcarbazepine related compound E AND Delete footnote b AND Reletter the following footnotes in both the table and footnote definitions: c to b

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								d to c e to d
CALCIUM CARBONATE	IMPURITIES	*USP36–NF31*	2747	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Acceptance criteria* in *Limit of Fluoride*: Change 50 ppm to: NMT 50 ppm AND Line 1 of *Acceptance criteria* in *Mercury, Method IIa <261>*: Change 0.5 ppm to: NMT 0.5 ppm
CRYOPRESERVED HUMAN FIBROBLAST-DERIVED DERMAL SUBSTITUTE	*Total collagen content*	*USP36–NF31*	3155	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 7 of *Collagen calibration standards*: Change by adding 25 mL, 50 mL, 100 mL, and 200 mL, to: by adding 25

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
EDETATE DISODIUM	ASSAY/ *Procedure*	*USP36–NF31*	3370	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	?L, 50 ?L, 100 ?L, and 200 ?L, Line 16 of *Analysis*: Change Calculate the percentage of edetate disodium to: Calculate the weight of edetate disodium AND Line 19 of *Analysis*: Change Result = $(V_T/V_U) \times W \times (M_{r1}/M_{r2}) \times 100$ to: Result = $(V_T/V_U) \times W \times (M_{r1}/M_{r2})$
LEVOFLOXACIN	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP36–NF31*	4099	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2 of USP Levofloxacin Related Compound A RS: Change (*S*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-9-Fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*][1,4-benzoxazine-6-carbocylic acid. to: (*S*)-9-Fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*][1,4]benzoxazine-6-carboxylic acid. AND Line 2 of USP Levofloxacin Related Compound B RS: Change (*S*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-9,10-Difluoro-3-methyl-7-oxo-2, 3-di hydro-7*H* -p yrido [1,2,3-*de*][1,4-benzoxazine-6-carbocylic acid. to: (*S*)-9,10-Difluoro-3-methyl-7-oxo-2, 3-di hydro-7*H* -p yrido [1,2,3-*de*][1,4]benzoxazine-6-carboxylic acid.
VENLAFAXINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP36–NF31*	5551	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2 of Venlafaxine Related Compound A RS: Change 1-(1-(4-methoxyphenyl)-2-(meth

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ylamino)ethyl)cyclohexanol. $C_{16}H_{25}NO_2$ 263.38 to: 1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol hydrochloride. $C_{16}H_{25}NO_2 \cdot HCl$ 299.84
STINGING NETTLE	COMPOSITION */Content of Total Amino Acids*	*USP36–NF31*	1604	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Reagent solution*: Change Solution containing 1.00 g of ninhydrin, 1.50 g of hydrindantin, to: Solution containing 1.00 g of ninhydrin, 150 mg of hydrindantin,
GENTAMICIN SULFATE	IM PURITIES/*Limit of Methanol*	*First Supplement to USP36–NF31*	5990	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 11 of *Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Result = $(R_U/R_S) \times (C_S/C_U) \times D \times F \times 100$ to: Result = $(R_U/R_S) \times (C_S/C_U) \times D \times F$ AND Line 18 of *Analysis*: Change C_S = percentage of methanol in the *Standard solution* (% v/v) to: C_S = percentage of methanol in the *Standard solution* AND Line 23 of *Analysis*: Change F = conversion factor, 0.001 g/mg to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								F = conversion factor, 1000 mg/g
AMOXICILLIN	IM PUR ITIES/*Organic Impuri ties*/*Procedure*	*USP36–NF31*	2477	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2 of *Acceptance criteria*: Change [Note—The reporting limit is 0.03% of the amoxicillin peak from the *Standard solution*.] to: [Note—The reporting limit is 0.03 times the amoxicillin peak from the *Standard solution*.]
CLARITHROMYCIN EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*/*Test 4*	*USP36–NF31*	3019	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2 of *Standard solution*: Change and *Medium* (96:4). to: and *Medium* (4:96).
DIPHENHYDR	*Assay*	*USP36–NF31*	3277	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First*	Line 2: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
AMINE HYDRO CHLORIDE ORAL SOLUTION							*Supplement to USP37–NF32*	*Mobile phase*, *Standard preparation*, *System suitability solution*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Diphenhydramine Hydrochloride*. to: *Mobile phase*—Prepare a solution of acetonitrile, water, and triethylamine (50: 50: 0.5), adjust with glacial acetic acid to a pH of 6.5, filter, and degas. Make adjustments if necessary (see *System Suitability* under

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Chromatography <621>). *Standard preparation* —Dissolve an accurately weighed quantity of USP Diphenhydramine Hydrochloride RS in water to obtain a solution having a known concentration of about 0.5 mg per mL. AND After the *Assay preparation* subsection: Add *System suitability solution* —Dissolve about 5 mg of benzophenone in 5 mL of acetonitrile,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dilute with water to 100 mL, and mix. Transfer 1.0 mL of this solution and 5 mg of diphenhydramine hydrochloride to a 10-mL volumetric flask, dilute with water to volume, and mix. *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 25-cm column that contains packing L10. The flow rate is about 1 mL per minute. Chromatograph the *System*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								suitability solution, and record the peak responses as directed for *Procedure*; the resolution, *R*, between the benzophenone and diphenhydramine peaks is not less than 2.0. Chromatograph replicate injections of the *Standard preparation*, and record the peak responses as directed for *Procedure*; the relative standard deviation is not more than 2.0%, and the tailing factor for the diphenhydramine hydrochloride

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								peak is not more than 2.0. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Diphenhydramine Hydrochloride*. to: Separately inject equal volumes, about 10 ?L, of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
FLUPHENAZIN	*Assay*	*USP36–NF31*	3639	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First*	Line 11 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
E DECANOATE INJECTION							*Supplement to USP37–NF32*	*Standard preparation*: Delete (1:5) AND Line 8 of *Assay preparation*: Delete (1:5)
OLMESARTAN MEDOXOMIL	IMPURITIES/*Organic Impurities/Impurity Table*	*USP36–NF31*	4570	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Footnote d: Change ((5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2′-(1-trityl-1*H*-tetrazol-5-yl)biphenyl-4-yl)methyl)-1*H*-imidazole-5-carboxylate. to: (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2′-(2-trityl-1*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-tetrazol-5-yl)biphenyl-4-yl)methyl)-1*H*-imidazole-5-carboxylate.

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 32
- Page 33
- Page 34
- Page 35
- Page 36
- Page 37
- Page 38
- Page 39
- Page 40
- Next page Next ›
- Last page Last »